# EDGAR Filing Document

**Accession Number:** 0001944285
**File Stem:** 0001145549-25-047655
**Filing Date:** 2025-7
**Character Count:** 27250
**Document Hash:** 0d535cc67bbf0925d1d1a519caa5aff1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001145549-25-047655.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001145549-25-047655

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250531

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**PERIOD START**: 20260228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tema ETF Trust
- **CENTRAL INDEX KEY:** 0001944285

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23823
- **FILM NUMBER:** 251147740

**BUSINESS ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036
- **BUSINESS PHONE:** 3024994928 EXT. 801

**MAIL ADDRESS:**
- **STREET 1:** 1919 M STREET, N.W., SUITE 700
- **CITY:** WASHINGTON
- **STATE:** DC
- **ZIP:** 20036

## Series and Classes Contracts Data

### Tema Heart & Health ETF (Series ID: S000081541)

| Class ID   | Class Name              | Ticker Symbol   |
|:---|:---|:---|
| C000244455 | Tema Heart & Health ETF | HRTS            |

## Nport-Ex

---

| | | |
|:---|:---|:---|
| **Tema GLP-1, Obesity & Cardiometabolic ETF** | **Tema GLP-1, Obesity & Cardiometabolic ETF** | **Tema GLP-1, Obesity & Cardiometabolic ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** | **May 31, 2025 (Unaudited)** |
| **COMMON STOCKS - 99.1%** | **Shares** | **Value**  |
| **Biotechnology - 34.7%<sup>(a)</sup>** | **Biotechnology - 34.7%<sup>(a)</sup>** | |
| AbbVie, Inc. | 6333 | $1178635 |
| Akero Therapeutics, Inc. <sup>(b)</sup> | 10695 | 531007 |
| Alnylam Pharmaceuticals, Inc. <sup>(b)</sup> | 3463 | 1054691 |
| Amgen, Inc. | 3248 | 936009 |
| Arrowhead Pharmaceuticals, Inc. <sup>(b)</sup> | 36943 | 593674 |
| Ascendis Pharma AS - ADR <sup>(b)</sup> | 4254 | 692721 |
| Bridgebio Pharma, Inc. <sup>(b)</sup> | 47911 | 1640952 |
| Crinetics Pharmaceuticals, Inc. <sup>(b)</sup> | 47059 | 1435770 |
| Cytokinetics, Inc. <sup>(b)</sup> | 25068 | 777609 |
| Gilead Sciences, Inc. | 15162 | 1669033 |
| Insmed, Inc. <sup>(b)</sup> | 10282 | 716964 |
| Intellia Therapeutics, Inc. <sup>(b)</sup> | 17112 | 117559 |
| Ionis Pharmaceuticals, Inc. <sup>(b)</sup> | 20731 | 694696 |
| Madrigal Pharmaceuticals, Inc. <sup>(b)</sup> | 1881 | 517764 |
| Mereo Biopharma Group PLC - ADR <sup>(b)</sup> | 115837 | 249049 |
| Metsera, Inc. <sup>(b)</sup> | 5669 | 151476 |
| Mirum Pharmaceuticals, Inc. <sup>(b)</sup> | 10387 | 461806 |
| Regeneron Pharmaceuticals, Inc. | 2018 | 989385 |
| Rocket Pharmaceuticals, Inc. <sup>(b)</sup> | 33462 | 83990 |
| Scholar Rock Holding Corp. <sup>(b)</sup> | 10773 | 312525 |
| Vertex Pharmaceuticals, Inc. <sup>(b)</sup> | 3783 | 1672275 |
| Viking Therapeutics, Inc. <sup>(b)</sup> | 20635 | 553018 |
| Zealand Pharma AS <sup>(b)</sup> | 11192 | 772537 |
|  |  | 17803145 |
| **Health Care Equipment & Supplies - 18.9%** | **Health Care Equipment & Supplies - 18.9%** |  |
| Abbott Laboratories | 18097 | 2417397 |
| Boston Scientific Corp. <sup>(b)</sup> | 17985 | 1893101 |
| Dexcom, Inc. <sup>(b)</sup> | 9552 | 819562 |
| Edwards Lifesciences Corp. <sup>(b)</sup> | 15023 | 1175099 |
| Insulet Corp. <sup>(b)</sup> | 3754 | 1220163 |
| Masimo Corp. <sup>(b)</sup> | 4125 | 670312 |
| Medtronic PLC | 18298 | 1518368 |
|  |  | 9714002 |
| **Health Care Providers & Services - 5.7%** | **Health Care Providers & Services - 5.7%** |  |
| McKesson Corp. | 1441 | 1036814 |
| UnitedHealth Group, Inc. | 6341 | 1914411 |
|  |  | 2951225 |
| **Life Sciences Tools & Services - 5.9%** | **Life Sciences Tools & Services - 5.9%** |  |
| Danaher Corp. | 5413 | 1027929 |
| Gubra AS <sup>(b)</sup> | 3858 | 228779 |
| Thermo Fisher Scientific, Inc. | 3353 | 1350655 |
| West Pharmaceutical Services, Inc. | 2060 | 434351 |
|  |  | 3041714 |
| **Pharmaceuticals - 33.9%<sup>(a)</sup>** | **Pharmaceuticals - 33.9%<sup>(a)</sup>** |  |
| AstraZeneca PLC | 15445 | 2230806 |
| Bristol-Myers Squibb Co. | 23314 | 1125600 |
| Chugai Pharmaceutical Co. Ltd. | 24261 | 1278510 |
| Eli Lilly & Co. | 6697 | 4940176 |
| Merck & Co., Inc. | 16395 | 1259792 |
| Novartis AG | 14322 | 1636328 |
| Novo Nordisk AS | 34163 | 2358911 |
| Roche Holding AG - ADR | 50982 | 2054574 |
| Structure Therapeutics, Inc. - ADR <sup>(b)</sup> | 23904 | 520151 |
|  |  | 17404848 |
| **TOTAL COMMON STOCKS** (Cost $55,126,352) | **TOTAL COMMON STOCKS** (Cost $55,126,352) | 50914934 |
| **SHORT-TERM INVESTMENTS - 1.2%** | **Shares** | **Value**  |
| **Money Market Funds - 1.2%** |  |  |
| First American Treasury Obligations Fund - Class X, 4.23% <sup>(c)</sup> | 598897 | 598897 |
| **TOTAL SHORT-TERM INVESTMENTS** (Cost $598,897) | **TOTAL SHORT-TERM INVESTMENTS** (Cost $598,897) | 598897 |
| **TOTAL INVESTMENTS - 100.3% (**Cost $55,725,249**)** | **TOTAL INVESTMENTS - 100.3% (**Cost $55,725,249**)** | $51513831 |
| Liabilities in Excess of Other Assets - (0.3)% | Liabilities in Excess of Other Assets - (0.3)% | (178986) |
| **TOTAL NET ASSETS - 100.0%** |  | $51334845 |
| two | two | –% |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | –% |
| The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. | The Global Industry Classification Standard ("GICS<sup>®</sup>") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor's Financial Services LLC ("S&P"). GICS<sup>®</sup> is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |

---

ADR - American Depositary Receipt <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
 industries or sectors.

(b) Non-income producing security.

(c) The rate shown represents the 7-day annualized effective yield as of May 31, 2025.

------

#### Tema ETF Trust

#### Tema GLP-1, Obesity & Cardiometabolic ETF
Notes to Quarterly Schedule of Investments

May 31, 2025 (Unaudited)

#### Investment Valuation
The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

**• Level 1** — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

**• Level 2** — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

**• Level 3** — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of May 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| <u>Investments:</u> |  |  |  |  |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $50914934 | $– | $– | $50914934 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 598897 | – | – | 598897 |
| Total Investments | $51513831 | $– | $– | $51513831 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

---

| | | |
|:---|:---|:---|
| **Allocation of Portfolio Holdings by Country as of May 31, 2025** | **Allocation of Portfolio Holdings by Country as of May 31, 2025** | |
| (% of Net Assets) | (% of Net Assets) |  |
| United States | $38493248 | 75.1% |
| Denmark | 4052948 | 7.8 |
| Switzerland | 3690902 | 7.2 |
| United Kingdom | 2479855 | 4.8 |
| Ireland | 1518368 | 2.9 |
| Japan | 1278510 | 2.5 |
| Liabilities in Excess of Other Assets | (178986) | (0.3) |
|  | $**51334845** | 100.0<br> **%** |

---

---

| | | |
|:---|:---|:---|
| **Sector Classification as of May 31, 2025** | **Sector Classification as of May 31, 2025** | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (% of Net Assets) |  |  |
| Health Care | $50914934 | 99.1% |
| Money Market Funds | 598897 | 1.2 |
| Liabilities in Excess of Other Assets | (178986) | (0.3) |
|  | **51334845** | 100.0<br> **%** |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Tema ETF Trust

- **b. Investment Company Act file number:** 811-23823

- **c. CIK number of Registrant:** 0001944285

- **d. LEI of Registrant:** 549300JKGDXNE2CLUY37

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 200 Vesey Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10281

  - **Telephone number:** 3024994928 EXT 801

**Item A.2. Information about the Series.**

- **a. Name of Series:** Tema GLP-1, Obesity & Cardiometabolic ETF

- **b. EDGAR series identifier (if any):** S000081541

- **c. LEI of Series:** 5299002XY0MZ4FAXPP90

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-02-28

- **b. Date as of which information is reported:** 2025-05-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $51569196.79

**Total Liabilities:** $234682.68

**Net Assets:** $51334514.11

**Delayed Delivery Securities:** $201172.35

**Cash Not Reported:** $0.02

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000244455 | -5.10%               | 0.01%                | -5.73%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $239909.61               | $-3698934.93                               |
| Month 2  | $422420.21               | $-652623.80                                |
| Month 3  | $-297240.85              | $-2891401.66                               |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                           | Title                                    | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| First American Treasury Obliga | First American Treasury Obligations Fund | CUSIP: 31846V328<br>LEI: 549300UU586IAH2B8H03 | Long             | STIV             | RF                | US        |    598897 | NS      | $598897.17    | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                 | Eli Lilly & Co                           | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |      6697 | NS      | $4940175.99   | 9.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                 | Merck & Co Inc                           | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |     16395 | NS      | $1259791.80   | 2.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Metsera Inc                    | Metsera Inc                              | CUSIP: 59267L107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5669 | NS      | $151475.68    | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp                   | Insulet Corp                             | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |      3754 | NS      | $1220162.62   | 2.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                    | Novartis AG                              | CUSIP: N/A<br>LEI: 5493007HIVTX6SY6XD66       | Long             | EC               | CORP              | CH        |     14322 | NS      | $1636327.65   | 3.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp      | Scholar Rock Holding Corp                | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |     10773 | NS      | $312524.73    | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Mirum Pharmaceuticals Inc      | Mirum Pharmaceuticals Inc                | CUSIP: 604749101<br>LEI: 254900YZKR40F7F27K81 | Long             | EC               | CORP              | US        |     10387 | NS      | $461806.02    | 0.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc   | Thermo Fisher Scientific Inc             | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |      3353 | NS      | $1350655.46   | 2.63%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc         | UnitedHealth Group Inc                   | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |      6341 | NS      | $1914411.31   | 3.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Akero Therapeutics Inc         | Akero Therapeutics Inc                   | CUSIP: 00973Y108<br>LEI: 549300SI3KG74LBE2955 | Long             | EC               | CORP              | US        |     10695 | NS      | $531006.75    | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                | AstraZeneca PLC                          | CUSIP: N/A<br>LEI: PY6ZZQWO2IZFZC3IOL08       | Long             | EC               | CORP              | GB        |     15445 | NS      | $2230805.71   | 4.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Boston Scientific Corp         | Boston Scientific Corp                   | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |     17985 | NS      | $1893101.10   | 3.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                   | Danaher Corp                             | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |      5413 | NS      | $1027928.70   | 2.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc            | Gilead Sciences Inc                      | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |     15162 | NS      | $1669032.96   | 3.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Abbott Laboratories            | Abbott Laboratories                      | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |     18097 | NS      | $2417397.26   | 4.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co        | Bristol-Myers Squibb Co                  | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |     23314 | NS      | $1125599.92   | 2.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Crinetics Pharmaceuticals Inc  | Crinetics Pharmaceuticals Inc            | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |     47059 | NS      | $1435770.09   | 2.80%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                     | Insmed Inc                               | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     10282 | NS      | $716963.86    | 1.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc      | Ionis Pharmaceuticals Inc                | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     20731 | NS      | $694695.81    | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| McKesson Corp                  | McKesson Corp                            | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |      1441 | NS      | $1036813.91   | 2.02%             |  |  |  | No            |                  1 | On Loan: No      |
| West Pharmaceutical Services I | West Pharmaceutical Services Inc         | CUSIP: 955306105<br>LEI: 5493007NKRGM1RJQ1P16 | Long             | EC               | CORP              | US        |      2060 | NS      | $434351.00    | 0.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                      | Amgen Inc                                | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      3248 | NS      | $936008.64    | 1.82%             |  |  |  | No            |                  1 | On Loan: No      |
| Arrowhead Pharmaceuticals Inc  | Arrowhead Pharmaceuticals Inc            | CUSIP: 04280A100<br>LEI: 549300O3CSB8T7OZ3D66 | Long             | EC               | CORP              | US        |     36943 | NS      | $593674.01    | 1.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                     | Dexcom Inc                               | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |      9552 | NS      | $819561.60    | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc      | Intellia Therapeutics Inc                | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |     17112 | NS      | $117559.44    | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Madrigal Pharmaceuticals Inc   | Madrigal Pharmaceuticals Inc             | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |      1881 | NS      | $517764.06    | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Structure Therapeutics Inc     | Structure Therapeutics Inc               | CUSIP: 86366E106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     23904 | NS      | $520151.04    | 1.01%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                     | AbbVie Inc                               | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |      6333 | NS      | $1178634.63   | 2.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc           | Bridgebio Pharma Inc                     | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     47911 | NS      | $1640951.75   | 3.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd   | Chugai Pharmaceutical Co Ltd             | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |     24261 | NS      | $1278509.77   | 2.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Rocket Pharmaceuticals Inc     | Rocket Pharmaceuticals Inc               | CUSIP: 77313F106<br>LEI: 549300R7VV82YUIN4Y93 | Long             | EC               | CORP              | US        |     33462 | NS      | $83989.62     | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma A/S             | Zealand Pharma A/S                       | CUSIP: N/A<br>LEI: 549300ITBB1ULBL4CZ12       | Long             | EC               | CORP              | DK        |     11192 | NS      | $772537.60    | 1.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Gubra A/S                      | Gubra A/S                                | CUSIP: N/A<br>LEI: 254900T17RRFZONO6W53       | Long             | EC               | CORP              | DK        |      3858 | NS      | $228778.81    | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc    | Alnylam Pharmaceuticals Inc              | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      3463 | NS      | $1054691.28   | 2.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S            | Ascendis Pharma A/S                      | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      4254 | NS      | $692721.36    | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Edwards Lifesciences Corp      | Edwards Lifesciences Corp                | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |     15023 | NS      | $1175099.06   | 2.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc     | Vertex Pharmaceuticals Inc               | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |      3783 | NS      | $1672275.15   | 3.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc               | Cytokinetics Inc                         | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     25068 | NS      | $777609.36    | 1.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Masimo Corp                    | Masimo Corp                              | CUSIP: 574795100<br>LEI: 549300Q4A8JK0PIYCU29 | Long             | EC               | CORP              | US        |      4125 | NS      | $670312.50    | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Mereo Biopharma Group PLC      | Mereo Biopharma Group PLC                | CUSIP: 589492107<br>LEI: 213800U8JQHIJOS5AS09 | Long             | EC               | CORP              | GB        |    115837 | NS      | $249049.55    | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc  | Regeneron Pharmaceuticals Inc            | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      2018 | NS      | $989385.04    | 1.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG               | Roche Holding AG                         | CUSIP: 771195104<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     50982 | NS      | $2054574.60   | 4.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc        | Viking Therapeutics Inc                  | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |     20635 | NS      | $553018.00    | 1.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S               | Novo Nordisk A/S                         | CUSIP: N/A<br>LEI: 549300DAQ1CVT6CXN342       | Long             | EC               | CORP              | DK        |     34163 | NS      | $2358910.95   | 4.60%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                  | Medtronic PLC                            | CUSIP: N/A<br>LEI: 549300GX3ZBSQWUXY261       | Long             | EC               | CORP              | IE        |     18298 | NS      | $1518368.04   | 2.96%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-07-23

**Name of Applicant:** Tema ETF Trust

**Signature:** /s/ Josh Hunter

**Name of Signer:** Josh Hunter

**Title:** Treasurer